Anti-TAU antibodies
The humanized monoclonal IgG1 antibody AbA effectively targets hyperphosphorylated tau at threonine 231 to inhibit tau spread and reduce tau aggregates in Alzheimer's disease models, addressing the limitations of current therapies.
Patent Information
- Application Number
- PCT/US2025/019566
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-16
- Filing Date
- 2025-03-12
- Publication Date
- 2025-09-25
AI Technical Summary
Current anti-tau therapies have not shown efficacy in slowing the progression of tau pathology in Alzheimer's disease, highlighting the need for novel antibodies that can effectively target hyperphosphorylated tau and inhibit its spread between neurons.
Development of a humanized monoclonal IgG1 antibody, AbA, specifically designed to bind to hyperphosphorylated tau at threonine 231 (pT231), which is hypothesized to inhibit the transneuronal spread of tau pathology and slow down tau accumulation in the brain.
AbA significantly reduces the number of neurons containing tau aggregates and slows the progression of tau pathology in synaptically connected brain regions, demonstrating a 54% to 87% reduction in tau pathology over 2 to 8 months in mouse models.